Dipeptidyl peptidase-4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes.
Takahiro AbeYasuhiro MatsubayashiSayaka MuragishiAkihiro YoshidaHideki SuganamiKenichi FurusawaKazuya FujiharaShiro TanakaKohei KakuHirohito SonePublished in: Journal of diabetes investigation (2021)
Anagliptin affected HIC levels according to HIC baseline levels. Higher baseline HIC values might result in improved hyperglycemia through reduced HIC.